ARTICLE | Top Story

Leo gets rights to two AZ dermatology candidates

July 2, 2016 12:01 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:GSK) granted Leo Pharma A/S (Ballerup, Denmark) exclusive, global rights to tralokinumab ( CAT-354) for dermatological indications and European rights to brodalumab ( KHK4827). AZ and Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) terminated an existing deal covering brodalumab's European rights, AZ said Friday.

Leo is to pay AZ $115 million up front for rights to tralokinumab, a human IgG4 mAb against IL-13. AZ is eligible for $1 billion in milestones, plus tiered sales royalties. Leo said tralokinumab significantly improved Eczema Area and Severity Index (EASI) scores from baseline vs. placebo in a Phase IIb trial to treat atopic dermatitis. ...